文献速递冠心病

急性冠脉综合征患者经皮冠状动脉介入治疗后 durable polymer 与 biodegradable polymer 药物洗脱支架的比较:HOST-REDUCE-POLYTECH-ACS 试验

Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial.
PubMed 文献 · Circulation · 2020-11-18

该研究为研究者发起的随机、开放标签、裁定者盲法、多中心非劣效性试验,纳入 3413 例 ACS 患者,比较 DP-DES 与 BP-DES 的疗效与安全性。12 个月时患者导向复合终点 DP-DES 组 5.2%、BP-DES 组 6.4%(绝对风险差 -1.2%,非劣效 P<0.001),DP-DES 非劣于 BP-DES;器械导向复合终点 DP-DES 更低(2.6% vs 3.9%,HR 0.67,95%CI 0.46-0.98,P=0.038)。

要点

  • ACS 患者 PCI 后 12 个月,DP-DES 在患者导向复合终点上非劣于 BP-DES。
  • 器械导向复合终点 DP-DES 低于 BP-DES,主要因靶病变血运重建减少。
  • 自发性非致死性心梗与支架血栓发生率极低,两组无显著差异。

核心结论

  • 在 ACS 接受 PCI 的患者中,DP-DES 在 12 个月患者导向复合终点方面非劣于 BP-DES。

研究设计与样本

  • HOST-REDUCE-POLYTECH-ACS 为研究者发起的随机、开放标签、裁定者盲法、多中心非劣效性试验,比较 DP-DES 与 BP-DES 在 ACS 患者中的疗效与安全性。
  • 共 3413 例患者随机接受 DP-DES(1713 例)或 BP-DES(1700 例)。

主要发现

  • 12 个月患者导向复合终点(全因死亡、非致死性心肌梗死和任何再次血运重建的复合终点)发生率 DP-DES 组 5.2%、BP-DES 组 6.4%(绝对风险差 -1.2%,非劣效 P<0.001)。
  • 12 个月器械导向复合终点(心源性死亡、靶血管心肌梗死或靶病变血运重建的复合终点)DP-DES 组 2.6%、BP-DES 组 3.9%(HR 0.67,95%CI 0.46-0.98,P=0.038),主要因靶病变血运重建减少。
  • 自发性非致死性心肌梗死发生率 DP-DES 组 0.6%、BP-DES 组 0.8%(P=0.513),支架血栓发生率 DP-DES 组 0.1%、BP-DES 组 0.4%(P=0.174),两组均极低且无显著差异。

临床怎么用

  • 对于 ACS 接受 PCI 的患者,选用 DP-DES 在 12 个月患者导向复合终点上不劣于 BP-DES,且器械导向复合终点事件更低,可作为支架选择参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Large-scale randomized comparison of drug-eluting stents (DES) based on durable polymer versus biodegradable polymer technology is currently insufficient in patients with acute coronary syndrome (ACS). The present study aimed to prove the noninferiority of the durable polymer DES (DP-DES) compared with the biodegradable polymer DES (BP-DES) in such patients. METHODS: The HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases-Comparison of Reduction of Prasugrel Dose or Polymer Technology in ACS Patients) trial is an investigator-initiated, randomized, open-label, adjudicator-blinded, multicenter, noninferiority trial comparing the efficacy and safety of DP-DES and BP-DES in patients with ACS. The primary end point was a patient-oriented composite outcome (a composite of all-cause death, nonfatal myocardial infarction, and any repeat revascularization) at 12 months. The key secondary end point was device-oriented composite outcome (a composite of cardiac death, target-vessel myocardial infarction, or target lesion revascularization) at 12 months. RESULTS: A total of 3413 patients were randomized to receive the DP-DES (1713 patients) and BP-DES (1700 patients). At 12 months, patient-oriented composite outcome occurred in 5.2% in the DP-DES group and 6.4% in the BP-DES group (absolute risk difference, -1.2%; Pnoninferiority<0.001). The key secondary end point, device-oriented composite outcome, occurred less frequently in the DP-DES group (DP-DES vs BP-DES, 2.6% vs 3.9%; hazard ratio, 0.67 [95% CI, 0.46-0.98]; P=0.038), mostly because of a reduction in target lesion revascularization. The rate of spontaneous nonfatal myocardial infarction and stent thrombosis were extremely low, with no significant difference between the 2 groups (0.6% versus 0.8%; P=0.513 and 0.1% versus 0.4%; P=0.174, respectively). CONCLUSIONS: In ACS patients receiving percutaneous coronary intervention, DP-DES was noninferior to BP-DES with regard to patient-oriented composite outcomes at 12 months after index percutaneous coronary intervention. Registration: URL: https://wwwclinicaltrials.gov; Unique identifier: NCT02193971.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kim HS, Kang J, Hwang D, et al. Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial. Circulation. 2020. PMID: 33205662. doi:10.1161/CIRCULATIONAHA.120.051700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。